Gene · 57016
Papers1,760
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,760
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AKR1B10 Serves as a Specific Biomarker for the Identification of Hepatocellular Ballooning Degeneration in MASH Patients. | Liver Int | 2026 | 42237432 | PubTator, text mining | PubMed |
| Novel pyridazinone-based N-phenylacetamides as α-glucosidase-selective and dual α-glucosidase/aldose reductase inhibitors: Synthesis, SAR analysis, and cytotoxicity evaluation. | Bioorg Chem | 2026 | 42229346 | PubTator, text mining | PubMed |
| Transcriptomic and Proteomic Analyses Identify THBS2, VWF, NFASC, and AKR1B10 as Diagnostic Biomarkers for Advanced Fibrosis in NAFLD. | J Inflamm Res | 2026 | 42211234 | PubTator, text mining | PubMed |
| IER3 as an RFX5 transcriptional co-activator promotes hepatocellular carcinoma progression via AKR1B10-mediated p53 transcriptional regulation. | Discov Oncol | 2026 | 42209919 | PubTator, text mining | PubMed |
| Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing. | J Gastrointest Oncol | 2026 | 42169880 | PubTator, text mining | PubMed |
| Unlocking new frontiers in AKR1B10 inhibition and future opportunities. | Eur J Med Chem | 2026 | 42150245 | PubTator, text mining | PubMed |
| Loss of SALL1 Promotes Hepatocellular Carcinoma Growth and Is Associated with Poor Clinical Outcome. | Cancers (Basel) | 2026 | 42122151 | PubTator, text mining | PubMed |
| Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease. | Ann Hepatol | 2026 | 42019594 | PubTator, text mining | PubMed |
| Mitochondrial Hub Genes in Rheumatoid Arthritis Identified by Machine Learning and Mendelian Randomization with Experimental Validation. | J Inflamm Res | 2026 | 41929818 | PubTator, text mining | PubMed |
| Aldo-Keto Reductase Family 1 Member B10 as a Therapeutic Frontier: Advances in Inhibitor Design and Multimodal Approaches. | Med Res Rev | 2026 | 41918269 | PubTator, text mining | PubMed |
| Case Report: Serum AKR1B10 as a complementary marker for the detection of AFP-negative hepatocellular carcinoma - a report of two cases. | Front Med (Lausanne) | 2026 | 41907234 | PubTator, text mining | PubMed |
| Computational framework for therapeutic target discovery via perturbation simulation: application to cystic fibrosis airway disease. | Brief Bioinform | 2026 | 41883030 | PubTator, text mining | PubMed |
| Global molecular landscape of early MASLD progression in human obesity. | Elife | 2026 | 41870035 | PubTator, text mining | PubMed |
| Clinical Application of Peripheral Blood Biomarkers for Solid Tumors. | MedComm (2020) | 2026 | 41799938 | PubTator, text mining | PubMed |
| A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10. | Invest Ophthalmol Vis Sci | 2026 | 41789845 | PubTator, text mining | PubMed |
| Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations. | J Pathol | 2026 | 41771797 | PubTator, text mining | PubMed |
| Aster koraiensis Nakai: Insights into Its Phytoconstituents and Pharmacological Properties. | Pharmaceutics | 2026 | 41754924 | PubTator, text mining | PubMed |
| Posidonia oceanica (L.) Delile in Focus: In Vitro and In Vivo Evidence for Biomedical Potential. | Int J Mol Sci | 2026 | 41751863 | PubTator, text mining | PubMed |
| α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer. | Cell Death Dis | 2026 | 41723136 | PubTator, text mining | PubMed |
| Identification of pyroptosis-associated genes for the prediction of metabolic dysfunction-associated steatohepatitis based on interpretable machine learning models. | Biochem Biophys Res Commun | 2026 | 41722245 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57016/papers?page=2